{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:40:04Z","timestamp":1789760404005,"version":"4.0.1"},"reference-count":342,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"am","delay-in-days":344,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["MH-096463"],"award-info":[{"award-number":["MH-096463"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NS-076517"],"award-info":[{"award-number":["NS-076517"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000165","name":"Division of Chemistry","doi-asserted-by":"publisher","award":["CHE-1625735"],"award-info":[{"award-number":["CHE-1625735"]}],"id":[{"id":"10.13039\/100000165","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.pharmthera.2021.108035","type":"journal-article","created":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T20:09:36Z","timestamp":1637006976000},"page":"108035","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"special_numbering":"C","title":["GABAkines \u2013 Advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA receptors"],"prefix":"10.1016","volume":"234","author":[{"given":"Rok","family":"Cerne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Lippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Poe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingjie","family":"Ping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalit K.","family":"Golani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Witkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2021.108035_bb0005","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1159\/000056036","article-title":"Temporal lobectomy in children with intractable seizures","volume":"34","author":"Adelson","year":"2001","journal-title":"Pediatric Neurosurgery"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0010","first-page":"245","article-title":"Alprazolam compared to diazepam and placebo in the treatment of anxiety","volume":"41","author":"Aden","year":"1980","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0025","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.bcp.2005.12.022","article-title":"A role for AMPA receptors in mood disorders","volume":"71","author":"Alt","year":"2006","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108333","article-title":"Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABAA receptor positive allosteric modulator","volume":"181","author":"Althaus","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0035","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.yebeh.2016.12.024","article-title":"The synthetic neuroactive steroid SGE-516 reduces status epilepticus and neuronal cell death in a rat model of soman intoxication","volume":"68","author":"Althaus","year":"2017","journal-title":"Epilepsy & Behavior"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0040","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/j.bja.2018.12.006","article-title":"Analgesic potential of PF-06372865, an \u03b12\/\u03b13\/\u03b15 subtype-selective GABAA partial agonist, in humans","volume":"123","author":"van Amerongen","year":"2019","journal-title":"British Journal of Anaesthesia"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0055","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1476-5381.1983.tb11031.x","article-title":"The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate","volume":"79","author":"Anis","year":"1983","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0060","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jad.2021.02.027","article-title":"Number needed to treat and number needed to harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorder","volume":"285","author":"Arnaud","year":"2021","journal-title":"Journal of Affective Disorders"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0075","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S1054-3589(08)57004-9","article-title":"Subtype-selective GABA(A) receptor modulation yields a novel pharmacological profile: the design and development of TPA023","volume":"57","author":"Atack","year":"2009","journal-title":"Advances in Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0080","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/7854_2009_30","article-title":"GABAA receptor alpha2\/alpha3 subtype-selective modulators as potential nonsedating anxiolytics","volume":"2","author":"Atack","year":"2010","journal-title":"Current Topics in Behavioral Neurosciences"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0085","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.2174\/156802611795371350","article-title":"GABAA receptor subtype-selective modulators. I. \u03b12\/\u03b13-selective agonists as non-sedating anxiolytics","volume":"11","author":"Atack","year":"2011","journal-title":"Current Topics in Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0090","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1124\/jpet.105.089920","article-title":"TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for alpha2- and alpha3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates","volume":"316","author":"Atack","year":"2006","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0095","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1124\/jpet.109.157909","article-title":"Benzodiazepine binding site occupancy by the novel GABAA receptor subtype-selective drug 7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) in rats, primates, and humans","volume":"332","author":"Atack","year":"2010","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0100","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2147\/NDT.S185757","article-title":"Selective serotonin reuptake inhibitor-induced sexual dysfunction: Current management perspectives","volume":"16","author":"Atmaca","year":"2020","journal-title":"Neuropsychiatric Disease and Treatment"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0105","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1124\/jpet.109.158303","article-title":"Reducing abuse liability of GABAA\/benzodiazepine ligands via selective partial agonist efficacy at alpha1 and alpha2\/3 subtypes","volume":"332","author":"Ator","year":"2010","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0135","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/978-981-32-9705-0_19","article-title":"Current and novel psychopharmacological drugs for anxiety disorders","volume":"1191","author":"Bandelow","year":"2020","journal-title":"Advances in Experimental Medicine and Biology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0140","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.4103\/0972-2327.128688","article-title":"Epileptogenic networks and drug-resistant epilepsy: Present and future perspectives of epilepsy research-Utility for the epileptologist and the epilepsy surgeon","volume":"17","author":"Banerjee","year":"2014","journal-title":"Annals of Indian Academy of Neurology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112924","article-title":"An update into the medicinal chemistry of translocator protein (TSPO) ligands","volume":"209","author":"Barresi","year":"2021","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0155","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ijdevneu.2017.06.001","article-title":"Positive modulation of \u03b15 GABAA receptors in preadolescence prevents reduced locomotor response to amphetamine in adult female but not male rats prenatally exposed to lipopolysaccharide","volume":"61","author":"Batini\u0107","year":"2017","journal-title":"International Journal of Developmental Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0160","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.euroneuro.2018.05.014","article-title":"Attaining in vivo selectivity of positive modulation of \u03b13\u03b2\u03b32 GABAA receptors in rats: A hard task!","volume":"28","author":"Batini\u0107","year":"2018","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0170","first-page":"1129","article-title":"Hepatitis induced by alpidem (Ananxyl). Four cases, one of them fatal","volume":"18","author":"Baty","year":"1994","journal-title":"Gastroent\u00e9rologie Clinique et Biologique"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0175","doi-asserted-by":"crossref","first-page":"11158","DOI":"10.1523\/JNEUROSCI.23-35-11158.2003","article-title":"Individual properties of the two functional agonist sites in GABA(A) receptors","volume":"23","author":"Baumann","year":"2003","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0180","doi-asserted-by":"crossref","first-page":"12757","DOI":"10.1523\/JNEUROSCI.3340-09.2009","article-title":"Extrasynaptic GABAA receptors: Form, pharmacology, and function","volume":"29","author":"Belelli","year":"2009","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0185","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1152\/physrev.00017.2006","article-title":"GABA: A pioneer transmitter that excites immature neurons and generates primitive oscillations","volume":"87","author":"Ben-Ari","year":"2007","journal-title":"Physiological Reviews"},{"issue":"5","key":"10.1016\/j.pharmthera.2021.108035_bb0195","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s00213-021-05793-z","article-title":"Alprazolam-induced EEG spectral power changes in rhesus monkeys: A translational model for the evaluation of the behavioral effects of benzodiazepines","volume":"238","author":"Berro","year":"2021","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0200","author":"Besson"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0205","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/01.j.pain.0000460331.33385.e8","article-title":"GABAergic modulation in central sensitization in humans: A randomized placebo-controlled pharmacokinetic-pharmacodynamic study comparing clobazam with clonazepam in healthy volunteers","volume":"156","author":"Besson","year":"2015","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0210","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1152\/physrev.00036.2003","article-title":"Molecular structure and physiological functions of GABA(B) receptors","volume":"84","author":"Bettler","year":"2004","journal-title":"Physiological Reviews"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.120007","article-title":"Transdermal delivery of breakthrough therapeutics for the management of treatment-resistant and post-partum depression","volume":"591","author":"Bhattaccharjee","year":"2020","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0220","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1111\/epi.14555","article-title":"Progress report on new antiepileptic drugs: A summary of the fourteenth eilat conference on new antiepileptic drugs and devices (EILAT XIV). II. Drugs in more advanced clinical development","volume":"59","author":"Bialer","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2020.172996","article-title":"The \u03b12,3-selective potentiators of GABAA receptors, KRM-II-81 and MP-III-80, produce anxiolytic-like effects and block chemotherapy-induced hyperalgesia in mice without tolerance development","volume":"196","author":"Biggerstaff","year":"2020","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0235","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/17512433.2018.1500895","article-title":"A viewpoint on rational and irrational fixed-drug combinations","volume":"11","author":"B\u0142aszczyk","year":"2018","journal-title":"Expert Review of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174023","article-title":"Vasodilatory effects of a variety of positive allosteric modulators of GABAA receptors on rat thoracic aorta","volume":"899","author":"Boji\u0107","year":"2021","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0255","author":"Bryson"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0260","author":"Buhl"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.117277","article-title":"Zuranolone as an oral adjunct to treatment of Parkinsonian tremor: A phase 2, open-label study","volume":"421","author":"Bullock","year":"2021","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0270","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1093\/brain\/awz283","article-title":"Excitatory GABAergic signalling is associated with benzodiazepine resistance in status epilepticus","volume":"142","author":"Burman","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0275","first-page":"11","article-title":"The \u03b16 GABAA receptor positive allosteric modulator DK-I-56-1 reduces tic-related behaviors in mouse models of tourette syndrome","author":"Cadeddu","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0280","doi-asserted-by":"crossref","first-page":"7089","DOI":"10.1021\/jm058034a","volume":"48","author":"Carling","year":"2005","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0285","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0896-6273(02)00820-6","article-title":"Gain modulation from background synaptic input","volume":"35","author":"Chance","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0290","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/bcp.12413","article-title":"The central nervous system effects of the partial GABA-A\u03b12,3-selective receptor modulator AZD7325 in comparison with lorazepam in healthy males","volume":"78","author":"Chen","year":"2014","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0295","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1471-4159.2006.04206.x","article-title":"GABAA receptor associated proteins: A key factor regulating GABAA receptor function","volume":"100","author":"Chen","year":"2007","journal-title":"Journal of Neurochemistry"},{"issue":"27","key":"10.1016\/j.pharmthera.2021.108035_bb0300","doi-asserted-by":"crossref","first-page":"19343","DOI":"10.1074\/jbc.M113.479725","article-title":"Specificity of intersubunit general anesthetic binding sites in the transmembrane domain of the human \u03b11\u03b23\u03b32 GABAA receptor","volume":"288","author":"Chiara","year":"2013","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0305","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1111\/bph.14198","article-title":"Cerebellar \u03b16 -subunit-containing GABAA receptors: A novel therapeutic target for disrupted prepulse inhibition in neuropsychiatric disorders","volume":"175","author":"Chiou","year":"2018","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0310","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/269342a0","article-title":"Chlordiazepoxide selectively augments GABA action in spinal cord cell cultures","volume":"269","author":"Choi","year":"1977","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0315","doi-asserted-by":"crossref","first-page":"480","DOI":"10.7326\/M16-2458","article-title":"Systemic pharmacologic therapies for low back pain: A systematic review for an American college of physicians clinical practice guideline","volume":"166","author":"Chou","year":"2017","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.108035_bb6001","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1152\/jn.00539.2013","article-title":"EEG\u2011\u03b2\/\u03b3 spectral power elevation in rat: a translatable biomarker elicited by GABA(A\u03b12\/3)\u2011positive allosteric modulators at nonsedating anxiolytic doses","volume":"113","author":"Christian","year":"2015","journal-title":"Journal of Neurophysiology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0320","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.neuropharm.2018.11.031","article-title":"Zinc reduces antiseizure activity of neurosteroids by selective blockade of extrasynaptic GABA-A receptor-mediated tonic inhibition in the hippocampus","volume":"148","author":"Chuang","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0325","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1124\/jpet.119.261735","article-title":"Isobolographic analysis of antiseizure activity of the GABA type A receptor-modulating synthetic neurosteroids brexanolone and ganaxolone with tiagabine and midazolam","volume":"372","author":"Chuang","year":"2020","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0330","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.neuropharm.2016.12.009","article-title":"Effects of the synthetic neurosteroid ganaxolone on seizure activity and behavioral deficits in an Angelman syndrome mouse model","volume":"116","author":"Ciarlone","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0335","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/430248","article-title":"A review of the updated pharmacophore for the alpha 5 GABA(A) benzodiazepine receptor model","volume":"2015","author":"Clayton","year":"2015","journal-title":"International Journal Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0345","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0031-6997(25)00025-0","article-title":"Excitatory amino acid receptors in the vertebrate central nervous system","volume":"41","author":"Collingridge","year":"1989","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0350","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.1523\/JNEUROSCI.22-13-05572.2002","article-title":"Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the alpha 5 subunit of the GABAA receptor","volume":"22","author":"Collinson","year":"2002","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0355","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1146\/annurev.pharmtox.37.1.205","article-title":"Pharmacology and functions of metabotropic glutamate receptors","volume":"37","author":"Conn","year":"1997","journal-title":"Annual Review of Pharmacology and Toxicology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0360","author":"Cook"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0365","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s40263-019-00672-w","article-title":"Using matching-adjusted indirect comparisons and network meta-analyses to compare efficacy of brexanolone injection with selective serotonin reuptake inhibitors for treating postpartum depression","volume":"33","author":"Cooper","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0370","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3390\/neurolint13010007","article-title":"VALTOCO\u00ae (Diazepam Nasal Spray) for the acute treatment of intermittent stereotypic episodes of frequent seizure activity","volume":"13","author":"Cornett","year":"2021","journal-title":"Neurology International"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0375","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1159\/000506868","article-title":"Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications","volume":"89","author":"Cosci","year":"2020","journal-title":"Psychotherapy and Psychosomatics"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0385","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/nature04223","article-title":"BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain","volume":"438","author":"Coull","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0390","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1080\/13543776.2020.1746764","article-title":"GABAA receptor subtype modulators in medicinal chemistry: An updated patent review (2014-present)","volume":"30","author":"Crocetti","year":"2020","journal-title":"Expert Opinion on Therapeutic Patents"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127755","article-title":"\u201cProximity frequencies\u201d a new parameter to evaluate the profile of GABAAR modulators","volume":"34","author":"Crocetti","year":"2021","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0400","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/arclin\/acx120","article-title":"The residual medium and long-term cognitive effects of benzodiazepine use: An updated meta-analysis","volume":"33","author":"Crowe","year":"2018","journal-title":"Archives of Clinical Neuropsychology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0405","first-page":"2120","article-title":"Pregabalin versus sertraline in generalized anxiety disorder. An open label study","volume":"19","author":"Cvjetkovic-Bosnjak","year":"2015","journal-title":"European Review for Medical and Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2021.108035_bib2119","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1755-5949.2009.00109.x","article-title":"A multicenter, placebo-controlled, double-blind, randomized study of efficacy and safety of ocinaplon (DOV 273,547) in generalized anxiety disorder","volume":"16","author":"Czobor","year":"2010","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0410","author":"Dandurand"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0415","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.neuron.2020.09.037","article-title":"Relocation of an extrasynaptic GABAA receptor to inhibitory synapses freezes excitatory synaptic strength and preserves memory","volume":"109","author":"Davenport","year":"2021","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0420","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1124\/jpet.105.092320","article-title":"An inverse agonist selective for alpha5 subunit-containing GABAA receptors enhances cognition","volume":"316","author":"Dawson","year":"2006","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0435","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nn.3890","article-title":"Early depolarizing GABA controls critical-period plasticity in the rat visual cortex","volume":"18","author":"Deidda","year":"2015","journal-title":"Nature Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0445","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/nyas.14479","article-title":"Allopregnanolone and perampanel as adjuncts to midazolam for treating diisopropylfluorophosphate-induced status epilepticus in rats","volume":"1480","author":"Dhir","year":"2020","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112405","article-title":"Design, synthesis and biological evaluation of 7-substituted 4-phenyl-6H-imidazo[1,5-a]thieno[3,2-f] [1,4]diazepines as safe anxiolytic agents","volume":"200","author":"Di Capua","year":"2020","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0455","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.neuropharm.2010.11.026","article-title":"HZ166, a novel GABAA receptor subtype-selective benzodiazepine site ligand, is antihyperalgesic in mouse models of inflammatory and neuropathic pain","volume":"60","author":"Di Lio","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0460","doi-asserted-by":"crossref","first-page":"10682","DOI":"10.1523\/JNEUROSCI.1166-05.2005","article-title":"Evidence for a significant role of \u03b13-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines","volume":"25","author":"Dias","year":"2005","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0465","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19m12887","article-title":"Effects of open-label, adjunctive ganaxolone on persistent depression despite adequate antidepressant treatment in postmenopausal women: A pilot study","volume":"81","author":"Dichtel","year":"2020","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0470","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0022-3565(25)12039-9","article-title":"Intrathecal baclofen and muscimol, but not midazolam, are antinociceptive using the rat-formalin model","volume":"275","author":"Dirig","year":"1995","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0475","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.euroneuro.2020.09.636","article-title":"Add-on benzodiazepine treatment in patients with major depressive disorder - results from a European cross-sectional multicenter study","volume":"41","author":"Dold","year":"2020","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0480","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1038\/s41467-019-10800-1","article-title":"Modulation of extrasynaptic GABAA alpha 5 receptors in the ventral hippocampus normalizes physiological and behavioral deficits in a circuit specific manner","volume":"10","author":"Donegan","year":"2019","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0485","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s00213-019-05447-1","article-title":"Tolerance and dependence following chronic alprazolam treatment: quantitative observation studies in female rhesus monkeys","volume":"237","author":"Duke","year":"2020","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0490","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/cns.13046","article-title":"Pronounced antiepileptic activity of the subtype-selective GABAA-positive allosteric modulator PF-06372865 in the GAERS absence epilepsy model","volume":"25","author":"Duveau","year":"2018","journal-title":"CNS Neuroscience & Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0505","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.tips.2018.04.003","article-title":"An emerging circuit pharmacology of GABAA receptors","volume":"39","author":"Engin","year":"2018","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0510","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1517\/13543784.6.10.1319","article-title":"GABAB receptor agonists and antagonists: Pharmacological properties and therapeutic possibilities","volume":"6","author":"Enna","year":"1997","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0515","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1054-3589(06)54001-3","article-title":"The role of GABA in the mediation and perception of pain","volume":"54","author":"Enna","year":"2006","journal-title":"Advances in Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0520","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2340\/16501977-2211","article-title":"Efficacy and safety of oral baclofen in the management of spasticity: A rationale for intrathecal baclofen","volume":"49","author":"Ertzgaard","year":"2017","journal-title":"Journal of Rehabilitation Medicine"},{"key":"10.1016\/j.pharmthera.2021.108035_bib2111","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.neuropharm.2017.08.012","article-title":"Selective inhibition of extra-synaptic \u03b15-GABAA receptors by S44819, a new therapeutic agent","volume":"125","author":"Etherington","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0525","doi-asserted-by":"crossref","first-page":"11634","DOI":"10.1523\/JNEUROSCI.2301-16.2016","article-title":"Functional synaptic integration of forebrain GABAergic precursors into the adult spinal cord","volume":"36","author":"Etlin","year":"2016","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0530","first-page":"25","article-title":"The GABAB receptor-structure, ligand binding and drug development","author":"Evenseth","year":"2020","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.pharmthera.2021.108035_bb0555","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/ijnp\/pyab002","article-title":"Behavioral deficits induced by somatostatin-positive GABA neuron silencing are rescued by alpha 5 GABA-A receptor potentiation","volume":"24","author":"Fee","year":"2021","journal-title":"The International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bib2114","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.brainresbull.2017.03.001","article-title":"Pharmacological and antihyperalgesic properties of the novel \u03b12\/3 preferring GABAA receptor ligand MP-III-024","volume":"131","author":"Fischer","year":"2017","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0560","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.neuropharm.2010.08.011","article-title":"Anxiolytic-like effects of 8-acetylene imidazobenzodiazepines in a rhesus monkey conflict procedure","volume":"59","author":"Fischer","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0570","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1021\/acs.molpharmaceut.7b01013","article-title":"A novel orally available asthma drug candidate that reduces smooth muscle constriction and inflammation by targeting GABAA receptors in the lung","volume":"15","author":"Forkuo","year":"2018","journal-title":"Molecular Pharmaceutics"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0575","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1212\/WNL.33.5.637","article-title":"THIP treatment of Huntington\u2019s disease","volume":"33","author":"Foster","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0580","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s40263-014-0189-8","article-title":"Off-label prescribing of antiepileptic drugs in pharmacoresistant epilepsy: A cross-sectional drug utilization study of tertiary care centers in Italy","volume":"28","author":"Franco","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0585","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/jnc.15140","article-title":"Sex-dependent pronociceptive role of spinal \u03b15 -GABAA receptor and its epigenetic regulation in neuropathic rodents","volume":"156","author":"Franco-Enz\u00e1stiga","year":"2021","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0600","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40263-019-00605-7","article-title":"Pharmacotherapy of postpartum depression: Current approaches and novel drug development","volume":"33","author":"Frieder","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0605","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0014-2999(99)00013-8","article-title":"Changes of benzodiazepine receptors during chronic benzodiazepine administration in humans","volume":"368","author":"Fujita","year":"1999","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0610","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/(SICI)1098-2299(199805)44:1<21::AID-DDR4>3.0.CO;2-R","article-title":"Antiepileptogenic effects of the novel synthetic neuroactive steroid, ganaxolone, against pentylentetrazol-induced kindled seizures: Comparison with diazepam and valproate","volume":"44","author":"Gasior","year":"1998","journal-title":"Drug Development Research"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0615","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0165-6147(99)01318-8","article-title":"Neuroactive steroids: Potential therapeutic use in neurological and psychiatric disorders","volume":"20","author":"Gasior","year":"1999","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0620","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0028-3908(99)00190-2","article-title":"Acute and chronic effects of the synthetic neuroactive steroid, ganaxolone, against the convulsive and lethal effects of pentylenetetrazol in seizure-kindled mice: Comparison with diazepam and valproate","volume":"39","author":"Gasior","year":"2000","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0625","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nrn3249","article-title":"Regulation of neuronal GABA(B) receptor functions by subunit composition","volume":"13","author":"Gassmann","year":"2012","journal-title":"Nature Reviews. Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0635","series-title":"StatPearls","article-title":"Alprazolam","author":"George","year":"2021"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0640","first-page":"1","article-title":"Achieving clinical response in postpartum depression leads to improvement in health-related quality of life","author":"Gerbasi","year":"2021","journal-title":"Current Medical Research and Opinion"},{"issue":"3","key":"10.1016\/j.pharmthera.2021.108035_bb0645","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1089\/jwh.2020.8483","article-title":"Brexanolone in postpartum depression: Post Hoc analyses to help inform clinical decision-making","volume":"30","author":"Gerbasi","year":"2020","journal-title":"Journal of Women\u2019s Health (2002)"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0655","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1002\/oby.22969","article-title":"Antidepressant medications and weight change: A narrative review","volume":"28","author":"Gill","year":"2020","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0660","series-title":"Burger\u2019s medicinal chemistry and drug discovery","first-page":"121","article-title":"Anticonvulsants","author":"Gitto","year":"2010"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0680","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00004714-199008000-00002","article-title":"Relative abuse liability of different benzodiazepines in drug abusers","volume":"10","author":"Griffiths","year":"1990","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0690","first-page":"25","article-title":"The new dipeptide TSPO ligands: Design, synthesis and structure-anxiolytic activity relationship","author":"Gudasheva","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0695","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1056\/NEJMoa1815981","article-title":"Trial of SAGE-217 in patients with major depressive disorder","volume":"381","author":"Gunduz-Bruce","year":"2019","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0700","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1007\/s00213-016-4369-8","article-title":"Benzodiazepine and neuroactive steroid combinations in rats: Anxiolytic-like and discriminative stimulus effects","volume":"233","author":"Gunter","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0705","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1097\/j.pain.0000000000001267","article-title":"A randomised, placebo-controlled clinical trial with the \u03b12\/3\/5 subunit selective GABAA positive allosteric modulator PF-06372865 in patients with chronic low back pain","volume":"159","author":"Gurrell","year":"2018","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0710","doi-asserted-by":"crossref","first-page":"e1786","DOI":"10.1212\/WNL.0000000000007271","article-title":"Photosensitive epilepsy: Robust clinical efficacy of a selective GABA potentiator","volume":"92","author":"Gurrell","year":"2019","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.pharmthera.2021.108035_bb6003","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/cpdd.912","article-title":"Tolerability, and Pharmacokinetics of Multiple Repeated Oral Doses of the \u03b12\/3\/5-Subtype Selective GABAA\u00a0-Positive Allosteric Modulator PF-06372865 in Healthy Volunteers","volume":"10","author":"Gurrell","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0715","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1177\/0269881106072343","article-title":"Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers","volume":"21","author":"de Haas","year":"2007","journal-title":"Journal of Psychopharmacology (Oxford)"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0720","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1177\/0269881111415731","article-title":"The effects of TPA023, a GABAA\u03b12,3 subtype-selective partial agonist, on essential tremor in comparison to alcohol","volume":"26","author":"de Haas","year":"2012","journal-title":"J Psychopharmacol (Oxford)"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0725","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/BF00449811","article-title":"Pharmacology of the benzodiazepine receptor","volume":"238","author":"Haefely","year":"1989","journal-title":"European Archives of Psychiatry and Neurological Sciences"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0730","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0014-2999(84)90197-3","article-title":"Effects of intrathecally administered THIP, baclofen and muscimol on nociceptive threshold","volume":"103","author":"Hammond","year":"1984","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0735","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.eplepsyres.2017.05.001","article-title":"Anticonvulsant profile of the neuroactive steroid, SGE-516, in animal models","volume":"134","author":"Hammond","year":"2017","journal-title":"Epilepsy Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2021.108035_bb0740","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.tins.2020.10.011","article-title":"Regulation of GABAARs by transmembrane accessory proteins","volume":"44","author":"Han","year":"2020","journal-title":"Trends in Neurosciences"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0745","doi-asserted-by":"crossref","first-page":"15327","DOI":"10.1038\/s41598-017-15609-w","article-title":"The synthetic neuroactive steroid SGE-516 reduces seizure burden and improves survival in a Dravet syndrome mouse model","volume":"7","author":"Hawkins","year":"2017","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0750","first-page":"1","article-title":"Drugs most frequently involved in drug overdose deaths: United States, 2011\u20132016","volume":"67","author":"Hedegaard","year":"2018","journal-title":"National Vital Statistics Reports"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0760","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.1093\/neuros\/nyy480","article-title":"Convection-enhanced delivery of muscimol in patients with drug-resistant epilepsy","volume":"85","author":"Heiss","year":"2019","journal-title":"Neurosurgery"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0765","article-title":"Safety, tolerability, and pharmacokinetics of allopregnanolone as a regenerative therapeutic for Alzheimer\u2019s disease: A single and multiple ascending dose phase 1b\/2a clinical trial","volume":"6","author":"Hernandez","year":"2020","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0770","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1097\/j.pain.0000000000001515","article-title":"\u03b15GABAA receptors play a pronociceptive role and avoid the rate-dependent depression of the Hoffmann reflex in diabetic neuropathic pain and reduce primary afferent excitability","volume":"160","author":"Hern\u00e1ndez-Reyes","year":"2019","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0775","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF02741459","article-title":"The diversity of GABAA receptors. Pharmacological and electrophysiological properties of GABAA channel subtypes","volume":"18","author":"Hevers","year":"1998","journal-title":"Molecular Neurobiology"},{"issue":"4","key":"10.1016\/j.pharmthera.2021.108035_bb0785","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/jama.2020.22106","article-title":"Balancing the risks and benefits of benzodiazepines","volume":"325","author":"Hirschtritt","year":"2021","journal-title":"JAMA."},{"key":"10.1016\/j.pharmthera.2021.108035_bb0790","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40262-019-00801-0","article-title":"SAGE-217, A novel GABAA receptor positive allosteric modulator: Clinical pharmacology and tolerability in Randomized phase I dose-finding studies","volume":"59","author":"Hoffmann","year":"2020","journal-title":"Clinical Pharmacokinetics"},{"issue":"8","key":"10.1016\/j.pharmthera.2021.108035_bb0795","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/FBP.0b013e32835a7c7e","article-title":"Assessment of the effects of NS11394 and L-838417, \u03b12\/3 subunit-selective GABA(A) [corrected] receptor-positive allosteric modulators, in tests for pain, anxiety, memory and motor function","volume":"23","author":"Hofmann","year":"2012","journal-title":"Behavioural Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0800","first-page":"746","article-title":"Diazepam in newly admitted schizophrenics","volume":"24","author":"Hollister","year":"1963","journal-title":"Diseases of the Nervous System"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0810","doi-asserted-by":"crossref","first-page":"11496","DOI":"10.1523\/JNEUROSCI.2213-07.2007","article-title":"NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons","volume":"27","author":"Homayoun","year":"2007","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0815","first-page":"151","article-title":"The effect of intrathecal administration of muscimol on modulation of neuropathic pain symptoms resulting from spinal cord injury; An experimental study","volume":"2","author":"Hosseini","year":"2014","journal-title":"Emerg (Tehran)"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0820","first-page":"55","volume":"16","author":"Huang","year":"1999","journal-title":"Drug Design and Discovery"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0830","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1007\/s00213-019-05286-0","article-title":"Self-administration of benzodiazepine and cocaine combinations by male and female rhesus monkeys in a choice procedure: Role of \u03b11 subunit-containing GABAA receptors","volume":"236","author":"Huskinson","year":"2019","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0835","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0310057X1103900505","article-title":"Acute pain management in opioid-tolerant patients: A growing challenge","volume":"39","author":"Huxtable","year":"2011","journal-title":"Anaesthesia and Intensive Care"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0840","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3340\/jkns.2019.0031","article-title":"From resection to disconnection for seizure control in pediatric epilepsy children","volume":"62","author":"Hwang","year":"2019","journal-title":"Journal of Korean Neurosurgical Association"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0845","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21010334","article-title":"GABAA receptor ligands often interact with binding sites in the transmembrane domain and in the extracellular domain-can the promiscuity code be cracked?","volume":"21","author":"Iorio","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0850","doi-asserted-by":"crossref","first-page":"108","DOI":"10.7326\/0003-4819-33-1-108","article-title":"Addiction to barbiturates and the barbiturate abstinence syndrome","volume":"33","author":"Isbell","year":"1950","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0855","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3389\/fnmol.2019.00179","article-title":"Neurobiology and therapeutic potential of \u03b15-GABA type a receptors","volume":"12","author":"Jacob","year":"2019","journal-title":"Frontiers in Molecular Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0860","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.seizure.2018.05.013","article-title":"Seizure cluster: Definition, prevalence, consequences, and management","volume":"68","author":"Jafarpour","year":"2019","journal-title":"Seizure"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0865","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2147\/JEP.S242964","article-title":"Experimental GABA A receptor agonists and allosteric modulators for the treatment of focal epilepsy","volume":"13","author":"Jankovi\u0107","year":"2021","journal-title":"Journal of Experimental Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0870","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/0897190013515001","article-title":"Benzodiazepines: A major component in unintentional prescription drug overdoses with opioid analgesics","volume":"27","author":"Jann","year":"2014","journal-title":"Journal of Pharmacy Practice"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0875","doi-asserted-by":"crossref","first-page":"11495","DOI":"10.1074\/jbc.RA120.013452","article-title":"Photoaffinity labeling identifies an intersubunit steroid-binding site in heteromeric GABA type A (GABAA) receptors","volume":"295","author":"Jayakar","year":"2020","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0880","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00213-016-4506-4","article-title":"GABAA receptor occupancy by subtype selective GABAA\u03b12,3 modulators: PET studies in humans","volume":"234","author":"Jucaite","year":"2017","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0885","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/330163a0","article-title":"Postsynaptic fall in intracellular pH induced by GABA-activated bicarbonate conductance","volume":"330","author":"Kaila","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.108035_bib2113","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0031-6997(25)06888-7","article-title":"Tolerance to, and dependence on, some non-opiate psychotropic drugs","volume":"23","author":"Kalant","year":"1971","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmthera.2021.108035_bib2116","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0140-6736(17)31264-3","article-title":"Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial","volume":"390","author":"Kanes","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0895","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/(SICI)1520-6394(1996)4:6<257::AID-DA1>3.0.CO;2-9","article-title":"Onset of antidepressant activity: Reexamining the structure of depression and multiple actions of drugs","volume":"4","author":"Katz","year":"1996","journal-title":"Depression and Anxiety"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0900","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/sj.npp.1300341","article-title":"Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression","volume":"29","author":"Katz","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0905","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/386239a0","article-title":"Expression cloning of GABA B receptors uncovers similarity to metabotropic glutamate receptors","volume":"386","author":"Kaupmann","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0910","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1007\/s00213-018-4892-x","article-title":"Effect of ganaxolone in patients with posttraumatic stress disorder","volume":"235","author":"Kawada","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0915","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00213-015-4115-7","article-title":"Evaluation of the neuroactive steroid ganaxolone on social and repetitive behaviors in the BTBR mouse model of autism","volume":"233","author":"Kazdoba","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0920","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202000100","article-title":"Development of novel indole-linked pyrazoles as anticonvulsant agents: A molecular hybridization approach","volume":"354","author":"Kerzare","year":"2021","journal-title":"Archiv der Pharmazie (Weinheim)"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0930","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104737","article-title":"Synthesis of 4,6-diphenylpyrimidin-2-ol derivatives as new benzodiazepine receptor ligands","volume":"109","author":"Khoramjouy","year":"2021","journal-title":"Bioorganic Chemistry"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0935","doi-asserted-by":"crossref","first-page":"346","DOI":"10.4097\/kjae.2015.68.4.346","article-title":"Use of triazolam and alprazolam as premedication for general anesthesia","volume":"68","author":"Kim","year":"2015","journal-title":"Korean Journal of Anesthesiology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0945","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1176\/appi.ajp.2020.20020134","article-title":"Understanding the clinical effects and mechanisms of action of neurosteroids","volume":"178","author":"Kleinman","year":"2021","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0950","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0091-3057(79)90125-4","article-title":"Resolution of two biochemically and pharmacologically distinct benzodiazepine receptors","volume":"11","author":"Klepner","year":"1979","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0955","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature06493","article-title":"Reversal of pathological pain through specific spinal GABAA receptor subtypes","volume":"451","author":"Knabl","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0960","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.pain.2008.10.015","article-title":"Genuine antihyperalgesia by systemic diazepam revealed by experiments in GABAA receptor point-mutated mice","volume":"141","author":"Knabl","year":"2009","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0965","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/0028-3908(96)84642-9","article-title":"The pharmacology of adenylyl cyclase modulation by GABAB receptors in rat brain slices","volume":"35","author":"Knight","year":"1996","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0970","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1021\/acschemneuro.0c00295","article-title":"Imidazodiazepine anticonvulsant, KRM-II-81, produces novel, non-diazepam-like antiseizure effects","volume":"11","author":"Knutson","year":"2020","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.108035_bb0975","doi-asserted-by":"crossref","DOI":"10.1002\/ams2.582","article-title":"Comparison of diazepam and lorazepam for the emergency treatment of adult status epilepticus: a systemic review and meta-analysis","volume":"7","author":"Kobata","year":"2020","journal-title":"Acute Medicine and Surgery"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1005","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.pbb.2013.07.003","article-title":"Therapeutic potential of GABA(B) receptor ligands in drug addiction, anxiety, depression and other CNS disorders","volume":"110","author":"Kumar","year":"2013","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1015","first-page":"1","article-title":"Ganaxolone treatment for epilepsy patients: from pharmacology to place in therapy","author":"Lattanzi","year":"2021","journal-title":"Expert Review of Neurotherpeutics"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1020","first-page":"461","article-title":"Chronic diazepam treatment in psychiatric outpatients","volume":"43","author":"Laughren","year":"1982","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1025","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-018-0833-4","article-title":"Cryo-EM structure of the human \u03b11\u03b23\u03b32 GABAA receptor in a lipid bilayer","volume":"565","author":"Laverty","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1035","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/FBP.0000000000000542","article-title":"Effects of oxycodone and diazepam alone and in combination on operant nociception","volume":"31","author":"Leonard","year":"2020","journal-title":"Behavioural Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1040","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.neuropharm.2017.04.020","article-title":"Allopregnanolone decreases interictal spiking and fast ripples in an animal model of mesial temporal lobe epilepsy","volume":"121","author":"L\u00e9vesque","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1050","series-title":"Buffalo, NY: A dissertation submitted to the faculty of the Graduate School of the University at Buffalo","article-title":"Characterization of novel \u03b12\/\u03b13 subtype-selective GABAA receptor positive allosteric modulators","author":"Lewter","year":"2019"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1055","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1021\/acschemneuro.6b00447","article-title":"Antinociceptive effects of a novel \u03b12\/\u03b13 subtype selective GABAA receptor positive allosteric modulator","volume":"8","author":"Lewter","year":"2017","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1070","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1080\/00207454.2020.1732967","article-title":"Intravenous sodium valproate in status epilepticus: Review and Meta-analysis","volume":"131","author":"Liampas","year":"2021","journal-title":"The International Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1075","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00213-008-1401-7","article-title":"Contribution of alpha1 subunit-containing gamma-aminobutyric acidA (GABAA) receptors to motor-impairing effects of benzodiazepines in squirrel monkeys","volume":"203","author":"Licata","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1080","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s11689-017-9207-8","article-title":"A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome","volume":"9","author":"Ligsay","year":"2017","journal-title":"Journal of Neurodevelopmental Disorders"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1085","doi-asserted-by":"crossref","first-page":"7380","DOI":"10.1073\/pnas.0502579102","article-title":"Selective anxiolysis produced by ocinaplon, a GABA(A) receptor modulator","volume":"102","author":"Lippa","year":"2005","journal-title":"Proceedings of National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1090","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1016\/0024-3205(81)90498-7","article-title":"Differential ontogeny of type 1 and type 2 benzodiazepine receptors","volume":"28","author":"Lippa","year":"1981","journal-title":"Life Sciences"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1095","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/0091-3057(78)90368-4","article-title":"Relationship between benzodiazepine receptors and experimental anxiety in rats","volume":"9","author":"Lippa","year":"1978","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1100","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/0024-3205(82)90001-7","article-title":"Molecular substrates of anxiety: Clues from the heterogeneity of benzodiazepine receptors","volume":"31","author":"Lippa","year":"1982","journal-title":"Life Sciences"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1110","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2020.113045","article-title":"Suppressing effect of the novel positive allosteric modulator of the GABAB receptor, COR659, on locomotor hyperactivity induced by different drugs of abuse","volume":"400","author":"Lobina","year":"2021","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1115","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3389\/fncel.2017.00208","article-title":"Social isolation in early versus late adolescent mice is associated with persistent behavioral deficits that can be improved by neurosteroid-based treatment","volume":"11","author":"Locci","year":"2017","journal-title":"Frontiers in Cellular Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1125","first-page":"329","article-title":"The history of barbiturates a century after their clinical introduction","volume":"1","author":"L\u00f3pez-Mu\u00f1oz","year":"2005","journal-title":"Neuropsychiatric Disease and Treatment"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1130","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41467-019-14154-6","article-title":"Enhancing neuronal chloride extrusion rescues \u03b12\/\u03b13 GABAA-mediated analgesia in neuropathic pain","volume":"11","author":"Lorenzo","year":"2020","journal-title":"Nature Communications"},{"issue":"Suppl. 8","key":"10.1016\/j.pharmthera.2021.108035_bb1135","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/epi.12025","article-title":"How theories evolved concerning the mechanism of action of barbiturates","volume":"53","author":"L\u00f6scher","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1140","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/j.1528-1167.2006.00607.x","article-title":"Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs","volume":"47","author":"L\u00f6scher","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1145","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/epi.16832","article-title":"The ups and downs of alkyl-carbamates in epilepsy therapy: How does cenobamate differ?","volume":"62","author":"L\u00f6scher","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1150","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1126\/science.290.5489.131","article-title":"Molecular and neuronal substrate for the selective attenuation of anxiety","volume":"290","author":"L\u00f6w","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1155","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.bcp.2014.12.010","article-title":"GABAA \u03b15 subunit-containing receptors do not contribute to reversal of inflammatory-induced spinal sensitization as indicated by the unique selectivity profile of the GABAA receptor allosteric modulator NS16085","volume":"93","author":"de Lucas","year":"2015","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1160","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/epi4.12344","article-title":"Neurosteroid and benzodiazepine combination therapy reduces status epilepticus and long-term effects of whole-body sarin exposure in rats","volume":"4","author":"Lumley","year":"2019","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1165","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/030006058000800207","article-title":"Anxiolytic efficacy of alprazolam compared to diazepam and placebo","volume":"8","author":"Maletzky","year":"1980","journal-title":"The Journal of International Medical Research"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105792","article-title":"Searching for new anxiolytic agents among derivatives of 11-dialkylaminoethyl-2,3,4,5-tetrahydrodiazepino[1,2-a]benzimidazole","volume":"161","author":"Maltsev","year":"2021","journal-title":"European Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1175","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/s41422-020-0350-5","article-title":"Cryo-EM structures of inactive and active GABAB receptor","volume":"30","author":"Mao","year":"2020","journal-title":"Cell Research"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1180","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1021\/acs.jmedchem.9b01312","article-title":"Subtype selective \u03b3-aminobutyric acid type A receptor (GABAAR) modulators acting at the benzodiazepine binding site: An update","volume":"63","author":"Maramai","year":"2020","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1185","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.alcohol.2019.05.008","article-title":"Lorazepam versus chlordiazepoxide for the treatment of alcohol withdrawal syndrome and prevention of delirium tremens in general medicine ward patients","volume":"81","author":"March","year":"2019","journal-title":"Alcohol"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1190","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/BF00401620","article-title":"Increase of \u201cantianxiety\u201d activity and tolerance of behavioral depression during chronic administration of oxazepam","volume":"13","author":"Margules","year":"1968","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1195","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","article-title":"The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: An unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"The Lancet"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1200","doi-asserted-by":"crossref","first-page":"7810","DOI":"10.1021\/acs.jmedchem.7b00846","article-title":"Neuroactive steroids. 2. 3\u03b1-hydroxy-3\u03b2-methyl-21-(4-cyano-1H-pyrazol-1\u2032-yl)-19-nor-5\u03b2-pregnan-20-one (SAGE-217): A clinical next generation neuroactive steroid positive allosteric modulator of the (\u03b3-aminobutyric Acid)A receptor","volume":"60","author":"Martinez Botella","year":"2017","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1210","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41586-018-0832-5","article-title":"GABA A receptor signalling mechanisms revealed by structural pharmacology","volume":"565","author":"Masiulis","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1215","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/ejp.1554","article-title":"GABAergic modulation of secondary hyperalgesia: A randomized controlled 4-way crossover trial with the \u03b12-subunit preferring GABA positive allosteric modulator, N-desmethyl-clobazam in healthy volunteers","volume":"24","author":"Matthey","year":"2020","journal-title":"European Journal of Pain"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1225","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/75761","article-title":"Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype","volume":"3","author":"McKernan","year":"2000","journal-title":"Nature Neuroscience"},{"issue":"CD001905","key":"10.1016\/j.pharmthera.2021.108035_bb1230","article-title":"Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children","volume":"1","author":"McTague","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1235","article-title":"Status epilepticus drug ganaxolone shows benefit in refractory seizures","author":"Meglio","year":"2019","journal-title":"Neurology Live"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1240","author":"Meglio"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1245","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3389\/fendo.2018.00703","article-title":"A novel, synthetic, neuroactive steroid is effective at decreasing depression-like behaviors and improving maternal care in preclinical models of postpartum depression","volume":"9","author":"Mel\u00f3n","year":"2018","journal-title":"Frontiers in Endocrinology (Lausanne)"},{"key":"10.1016\/j.pharmthera.2021.108035_bib2115","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0140-6736(18)31551-4","article-title":"Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"392","author":"Meltzer-Brody","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2021.108035_bib2112","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1177\/0269881119882803","article-title":"Evaluation of the anti-conflict, reinforcing, and sedative effects of YT-III-31, a ligand functionally selective for\u2009\u03b13 subunit-containing GABAA receptors","volume":"34","author":"Meng","year":"2020","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1250","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.drugalcdep.2016.05.029","article-title":"Self-administration of progesterone and synthetic neuroactive steroids by male rhesus monkeys","volume":"165","author":"Meng","year":"2016","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1255","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.pbb.2018.04.009","article-title":"An antidepressant-related pharmacological signature for positive allosteric modulators of \u03b12\/3-containing GABAA receptors","volume":"170","author":"Methuku","year":"2018","journal-title":"Pharmacology Biochemistry and Behavior"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1260","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.tips.2009.12.005","article-title":"Binding, activation and modulation of Cys-loop receptors","volume":"31","author":"Miller","year":"2010","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1265","doi-asserted-by":"crossref","DOI":"10.1101\/338343","article-title":"Heteromeric GABA A receptor structures in positively-modulated active states","author":"Miller","year":"2018","journal-title":"Biophysics."},{"key":"10.1016\/j.pharmthera.2021.108035_bb1270","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0896-6273(03)00200-9","article-title":"Shunting inhibition modulates neuronal gain during synaptic excitation","volume":"38","author":"Mitchell","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1275","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.541802","article-title":"Neurosteroids and seizure activity","volume":"11","author":"Miziak","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1280","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.tins.2004.07.002","article-title":"Diversity of inhibitory neurotransmission through GABA(A) receptors","volume":"27","author":"Mody","year":"2004","journal-title":"Trends in Neurosciences"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1285","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/FBP.0000000000000464","article-title":"Effects of the \u03b12\/\u03b13-subtype-selective GABAA receptor positive allosteric modulator KRM-II-81 on pain-depressed behavior in rats: Comparison with ketorolac and diazepam","volume":"30","author":"Moerke","year":"2019","journal-title":"Behavioural Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1290","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s12031-018-1246-4","article-title":"The \u03b15-containing GABAA receptors-A brief summary","volume":"67","author":"Mohamad","year":"2019","journal-title":"Journal of Molecular Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1295","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1126\/science.918669","article-title":"Benzodiazepine receptor: Demonstration in the central nervous system","volume":"198","author":"M\u00f6hler","year":"1977","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1300","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.tips.2009.06.004","article-title":"Developing analgesics by enhancing spinal inhibition after injury: GABAA receptor subtypes as novel targets","volume":"30","author":"Munro","year":"2009","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1305","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1124\/jpet.108.144568","volume":"327","author":"Munro","year":"2008","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1310","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/0091-3057(88)90211-0","article-title":"Clinical studies with the new anxiolytic alpidem in anxious patients: An overview of the European experiences","volume":"29","author":"Musch","year":"1988","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1320","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1007\/s12035-018-1330-3","article-title":"Allopregnanolone treatment improves plasma metabolomic profile associated with GABA metabolism in fragile X-associated tremor\/ataxia syndrome: A pilot study","volume":"56","author":"Napoli","year":"2019","journal-title":"Molecular Neurobiology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1325","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104504","article-title":"5-[Aryloxypyridyl (or nitrophenyl)]-4H-1,2,4-triazoles as novel flexible benzodiazepine analogues: Synthesis, receptor binding affinity and lipophilicity-dependent anti-seizure onset of action","volume":"106","author":"Navidpour","year":"2021","journal-title":"Bioorganic Chemistry"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1345","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/j.pain.0000000000002030","article-title":"The \u03b12\/\u03b13GABAA receptor modulator TPA023B alleviates not only the sensory but also the tonic affective component of chronic pain in mice","volume":"162","author":"Neumann","year":"2021","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1350","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1212\/WNL.0b013e318232de76","article-title":"Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome","volume":"77","author":"Ng","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1355","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00213-003-1527-6","article-title":"Evaluation of the phencyclidine-like discriminative stimulus effects of novel NMDA channel blockers in rats","volume":"170","author":"Nicholson","year":"2003","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1360","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/608912","article-title":"A comparison of the \u03b12\/3\/5 selective positive allosteric modulators L-838,417 and TPA023 in preclinical models of inflammatory and neuropathic pain","volume":"2011","author":"Nickolls","year":"2011","journal-title":"Advances in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1365","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/bph.14119","article-title":"Pharmacology in translation: The preclinical and early clinical profile of the novel \u03b12\/3 functionally selective GABAA receptor positive allosteric modulator PF-06372865","volume":"175","author":"Nickolls","year":"2018","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1370","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0166-2236(96)20019-0","article-title":"Metabotropic glutamate receptors: A new target for the therapy of neurodegenerative disorders?","volume":"19","author":"Nicoletti","year":"1996","journal-title":"Trends in Neurosciences"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1375","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202000342","article-title":"Synthesis and evaluation of anticonvulsant activity of some schiff bases of 7-Amino-1,3-dihydro-2H-1,4-benzodiazepin-2-one","volume":"17","author":"Nilkanth","year":"2020","journal-title":"Chemistry & Biodiversity"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1380","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.neuroscience.2018.11.045","article-title":"Genotype differences in sensitivity to the anticonvulsant effect of the synthetic neurosteroid ganaxolone during chronic ethanol withdrawal","volume":"397","author":"Nipper","year":"2019","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1400","doi-asserted-by":"crossref","first-page":"9637","DOI":"10.1021\/jacs.7b04206","article-title":"Synthesis of (\u2212)-11-O-debenzoyltashironin: Neurotrophic sesquiterpenes cause hyperexcitation","volume":"139","author":"Ohtawa","year":"2017","journal-title":"Journal of the American Chemical Society"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1405","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.bcp.2018.02.015","article-title":"Delineation of the functional properties and the mechanism of action of AA29504, an allosteric agonist and positive allosteric modulator of GABAA receptors","volume":"150","author":"Olander","year":"2018","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1410","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.neuropharm.2018.01.036","article-title":"GABAA receptor: Positive and negative allosteric modulators","volume":"136","author":"Olsen","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1415","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.neuropharm.2008.07.045","article-title":"GABA A receptors: Subtypes provide diversity of function and pharmacology","volume":"56","author":"Olsen","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1420","first-page":"5773","article-title":"Design and identification of a novel, functionally subtype selective GABAA positive allosteric modulator (PF-06372865)","volume":"62","author":"Owen","year":"2019","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1425","series-title":"BioPharma Dive","article-title":"Trial setback strikes blow to Sage antidepressant ambitions","author":"Pagliarulo","year":"2019"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1435","doi-asserted-by":"crossref","first-page":"242","DOI":"10.24820\/ark.5550190.p011.398","article-title":"Design, synthesis and characterization of novel gamma-aminobutyric acid type A receptor ligands","volume":"2020","author":"Pandey","year":"2020","journal-title":"ARKIVOC"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1440","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s41586-020-2469-4","article-title":"Structures of metabotropic GABAB receptor","volume":"584","author":"Papasergi-Scott","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1445","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/s41586-020-2452-0","article-title":"Structure of human GABAB receptor in an inactive state","volume":"584","author":"Park","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1450","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/archpsyc.1973.01750360007002","article-title":"National patterns of psychotherapeutic drug use","volume":"28","author":"Parry","year":"1973","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1455","article-title":"Brexanolone: A novel drug for the treatment of postpartum depression","author":"Patatanian","year":"2020","journal-title":"Journal of Pharmacy Practice"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1465","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4103\/0970-9185.150534","article-title":"A comparative study between oral melatonin and oral midazolam on preoperative anxiety, cognitive, and psychomotor functions","volume":"31","author":"Patel","year":"2015","journal-title":"Journal of Anaesthesiology Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1470","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/npp.2013.221","article-title":"Antihyperalgesia by \u03b12-GABAA receptors occurs via a genuine spinal action and does not Involve supraspinal sites","volume":"39","author":"Paul","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1475","first-page":"1","article-title":"Evaluating brexanolone for the treatment of postpartum depression","author":"Payne","year":"2021","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1485","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pediatrneurol.2019.11.008","article-title":"New and emerging medications for treatment of pediatric epilepsy","volume":"107","author":"Perry","year":"2020","journal-title":"Pediatric Neurology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1495","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.39383","article-title":"Cryo-EM structure of the benzodiazepine-sensitive \u03b11\u03b21\u03b32S tri-heteromeric GABAA receptor in complex with GABA","volume":"7","author":"Phulera","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1500","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1111\/j.1528-1167.2007.01182.x","article-title":"Clinical evaluation of ganaxolone in pediatric and adolescent patients with refractory epilepsy","volume":"48","author":"Pieribone","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1505","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.neuropharm.2018.11.003","article-title":"Neuroprotective action of diazepam at very low and moderate doses in Alzheimer\u2019s disease model rats","volume":"144","author":"Pilipenko","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1520","doi-asserted-by":"crossref","first-page":"10800","DOI":"10.1021\/acs.jmedchem.6b01332","article-title":"Synthesis and characterization of a novel gamma-aminobutyric acid type A (GABAA) receptor ligand that combines outstanding metabolic stability, pharmacokinetics, and anxiolytic efficacy","volume":"59","author":"Poe","year":"2016","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1525","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1060028019873320","article-title":"Brexanolone (Zulresso): Finally, an FDA-approved treatment for postpartum depression","volume":"54","author":"Powell","year":"2020","journal-title":"The Annals of Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1530","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1073\/pnas.0337591100","article-title":"Gain control of firing rate by shunting inhibition: Roles of synaptic noise and dendritic saturation","volume":"100","author":"Prescott","year":"2003","journal-title":"PNAS"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1535","first-page":"84","article-title":"Novel benzodiazepine-like ligands with various anxiolytic, antidepressant, or pro-cognitive profiles","volume":"5","author":"Prevot","year":"2019","journal-title":"Molecular Neuropsychiatry"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1540","doi-asserted-by":"crossref","first-page":"259","DOI":"10.5056\/jnm19186","article-title":"Efficacy and safety of clidinium\/chlordiazepoxide as an add-on therapy in functional dyspepsia: A randomized, controlled, trial","volume":"26","author":"Puasripun","year":"2020","journal-title":"Journal of Neurogastroenterology and Motility"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1555","series-title":"StatPearls","article-title":"Valproic acid","author":"Rahman","year":"2020"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1560","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s00213-021-05791-1","article-title":"Synergistic antihyperalgesic and antinociceptive effects of morphine and methyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate (MP-III-024): A positive allosteric modulator at \u03b12GABAA and \u03b13GABAA receptors","volume":"238","author":"Rahman","year":"2021","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1570","author":"Rakhit"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1575","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.neuropharm.2016.07.004","article-title":"The clobazam metabolite N-desmethyl clobazam is an \u03b12 preferring benzodiazepine with an improved therapeutic window for antihyperalgesia","volume":"109","author":"Ralvenius","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1580","doi-asserted-by":"crossref","first-page":"6803","DOI":"10.1038\/ncomms7803","article-title":"Analgesia and unwanted benzodiazepine effects in point-mutated mice expressing only one benzodiazepine-sensitive GABAA receptor subtype","volume":"6","author":"Ralvenius","year":"2015","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1585","author":"Ralvenius"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1590","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1038\/s41467-018-05709-0","article-title":"Itch suppression in mice and dogs by modulation of spinal \u03b12 and \u03b13GABAA receptors","volume":"9","author":"Ralvenius","year":"2018","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1595","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0022-3565(25)25804-9","article-title":"The psychosedative properties of methaminodiazepoxide","volume":"129","author":"Randall","year":"1960","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1600","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1007\/s00213-017-4649-y","article-title":"A randomized controlled trial of ganaxolone in posttraumatic stress disorder","volume":"234","author":"Rasmusson","year":"2017","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1605","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cotox.2019.08.001","article-title":"Mechanism-based novel antidotes for organophosphate neurotoxicity","volume":"14","author":"Reddy","year":"2019","journal-title":"Current Opinion in Toxicology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1610","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/epi.14693","article-title":"Extrasynaptic \u03b3-aminobutyric acid type A receptor-mediated sex differences in the antiseizure activity of neurosteroids in status epilepticus and complex partial seizures","volume":"60","author":"Reddy","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1615","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1528-1167.2010.02870.x","article-title":"Neurosteroids as endogenous regulators of seizure susceptibility and use in the treatment of epilepsy","volume":"51","author":"Reddy","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1620","series-title":"Jasper\u2019s basic mechanisms of the epilepsies","article-title":"Neurosteroids \u2014 endogenous regulators of seizure susceptibility and role in the treatment of epilepsy","author":"Reddy","year":"2012"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1625","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00213-014-3721-0","article-title":"Inhaled vs. oral alprazolam: subjective, behavioral and cognitive effects, and modestly increased abuse potential","volume":"232","author":"Reissig","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1635","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1021\/jm801652d","article-title":"Antiseizure activity of novel gamma-aminobutyric acid (A) receptor subtype-selective benzodiazepine analogues in mice and rat models","volume":"52","author":"Rivas","year":"2009","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1640","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2019.106537","article-title":"Diazepam buccal film for the treatment of acute seizures","volume":"101","author":"Rogawski","year":"2019","journal-title":"Epilepsy & Behavior"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1645","series-title":"Sage therapeutics R&D Day","volume":"2016","author":"Rosenthal","year":"2016"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1650","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/ana.25008","article-title":"Brexanolone as adjunctive therapy in super-refractory status epilepticus","volume":"82","author":"Rosenthal","year":"2017","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1655","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/44579","article-title":"Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes","volume":"401","author":"Rudolph","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1660","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nrd3502","article-title":"Beyond classical benzodiazepines: Novel therapeutic potential of GABA A receptor subtypes","volume":"10","author":"Rudolph","year":"2011","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1665","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1146\/annurev-pharmtox-011613-135947","article-title":"GABAA receptor subtypes: Therapeutic potential in Down syndrome, affective disorders, schizophrenia, and autism","volume":"54","author":"Rudolph","year":"2014","journal-title":"Annual Review of Pharmacology and Toxicology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1675","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pediatrneurol.2019.10.009","article-title":"PCDH19-related epilepsy syndrome: A comprehensive clinical review","volume":"105","author":"Samanta","year":"2020","journal-title":"Pediatric Neurology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1680","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2165\/11599020-000000000-00000","article-title":"GABA(A) receptor physiology and its relationship to the mechanism of action of the 1,5-benzodiazepine clobazam","volume":"26","author":"Sankar","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1685","doi-asserted-by":"crossref","first-page":"21176","DOI":"10.1073\/pnas.1902383116","article-title":"Photopotentiation of the GABAA receptor with caged diazepam","volume":"116","author":"Sansalone","year":"2019","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1690","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1124\/jpet.118.252155","article-title":"Intravenously administered ganaxolone blocks diazepam-resistant lithium-pilocarpine-induced status epilepticus in rats: Comparison with allopregnanolone","volume":"368","author":"Saporito","year":"2019","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1695","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1054-3589(08)60242-2","article-title":"Mechanisms of action of benzodiazepines","volume":"16","author":"Schallek","year":"1979","journal-title":"Advances in Pharmacology and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1700","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/0197-0186(94)90092-2","article-title":"Novel functions for subtypes of metabotropic glutamate receptors","volume":"24","author":"Schoepp","year":"1994","journal-title":"Neurochemistry International"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1705","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s40265-019-01121-0","article-title":"Brexanolone: First global approval","volume":"79","author":"Scott","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1710","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.sbi.2019.03.023","article-title":"A structural perspective on GABAA receptor pharmacology","volume":"54","author":"Scott","year":"2019","journal-title":"Current Opinion in Structural Biology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1715","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.nbd.2018.07.018","article-title":"Affective, neurocognitive and psychosocial disorders associated with traumatic brain injury and post-traumatic epilepsy","volume":"123","author":"Semple","year":"2019","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1720","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11030-019-09940-9","article-title":"Novel fused 1,2,3-triazolo-benzodiazepine derivatives as potent anticonvulsant agents: Design, synthesis, in vivo, and in silico evaluations","volume":"24","author":"Shafie","year":"2020","journal-title":"Molecular Diversity"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1725","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41586-020-2408-4","article-title":"Structural basis of the activation of a metabotropic GABA receptor","volume":"584","author":"Shaye","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1730","doi-asserted-by":"crossref","DOI":"10.1177\/2045125321997293","article-title":"Brexanolone: Panacea for postpartum depression? Reply to: \u201cIntravenous brexanolone for postpartum depression: what it is, how well does it work, and will it be used?\u201d","volume":"11","author":"Shukla","year":"2021","journal-title":"Therapeutic Advances in Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bib2120","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1021\/acschembio.8b00145","article-title":"Engineered Flumazenil Recognition Site Provides Mechanistic Insight Governing Benzodiazepine Modulation in GABAA Receptors","volume":"13","author":"Siebert","year":"2018","journal-title":"ACS Chem Biol"},{"issue":"4","key":"10.1016\/j.pharmthera.2021.108035_bib2118","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1124\/pr.117.014449","article-title":"International Union of Basic and Clinical Pharmacology. CVI: GABAA Receptor Subtype- and Function-selective Ligands: Key Issues in Translation to Humans","volume":"70","author":"Sieghart","year":"2018","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1735","doi-asserted-by":"crossref","first-page":"40224","DOI":"10.1074\/jbc.R112.386664","article-title":"Structure, function, and modulation of GABAA receptors","volume":"287","author":"Sigel","year":"2012","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1740","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/JCP.0000000000000997","volume":"39","author":"Simen","year":"2019","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1745","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nature04708","article-title":"Recent advances in Cys-loop receptor structure and function","volume":"440","author":"Sine","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1750","doi-asserted-by":"crossref","first-page":"3","DOI":"10.17712\/1658-3183.1826","article-title":"Definition of intractable epilepsy","volume":"16","author":"Sinha","year":"2011","journal-title":"Neurosciences (Riyadh)"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1755","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.tips.2012.08.003","article-title":"Anxioselective anxiolytics: On a quest for the Holy Grail","volume":"33","author":"Skolnick","year":"2012","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1760","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.bcp.2018.08.019","article-title":"Probing the molecular basis for affinity\/potency- and efficacy-based subtype-selectivity exhibited by benzodiazepine-site modulators at GABAA receptors","volume":"158","author":"S\u00f6derhielm","year":"2018","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1765","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ejmech.2019.03.043","article-title":"GABA allosteric modulators: An overview of recent developments in non-benzodiazepine modulators","volume":"171","author":"Solomon","year":"2019","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1770","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/epi.13705","article-title":"Randomized, double-blind, placebo-controlled phase 2 study of ganaxolone as add-on therapy in adults with uncontrolled partial-onset seizures","volume":"58","author":"Sperling","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1780","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/266732a0","article-title":"Benzodiazepine receptors in rat brain","volume":"266","author":"Squires","year":"1977","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1795","first-page":"879","article-title":"The withdrawal syndrome in benzodiazepine dependence and its management","volume":"113","author":"Str\u0103ulea","year":"2009","journal-title":"Revista Medico-Chirurgical\u0103\u0306 a Societ\u0103\u0306\u0163\u031cii de Medici \u015f\u0327i Naturali\u015f\u0327ti din Ia\u015f\u0327i"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1800","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40263-020-00784-8","article-title":"Expanding the treatment landscape for lennox-gastaut syndrome: current and future strategies","volume":"35","author":"Strzelczyk","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1805","first-page":"349","article-title":"Benzodiazepines as adjunctive therapy in treatment refractory symptoms of schizophrenia","volume":"29","author":"Szarmach","year":"2017","journal-title":"Psychiatria Danubina"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1810","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1126\/science.6101294","article-title":"Receptors for the age of anxiety: Pharmacology of the benzodiazepines","volume":"207","author":"Tallman","year":"1980","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1815","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nature08758","article-title":"Neural bases for addictive properties of benzodiazepines","volume":"463","author":"Tan","year":"2010","journal-title":"Nature"},{"issue":"Suppl. 2","key":"10.1016\/j.pharmthera.2021.108035_bb1825","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1528-1167.2008.02005.x","article-title":"Preventing and treating posttraumatic seizures: The human experience","volume":"50","author":"Temkin","year":"2009","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.108035_bb1830","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.amepre.2021.01.025","article-title":"Comparison of dental benzodiazepine prescriptions from the U.S., England, and Australia from 2013 to 2018","volume":"61","author":"Teoh","year":"2021","journal-title":"American Journal of Preventive Medicine"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1835","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.neuroscience.2018.11.053","article-title":"Sex differences in the temporal neuromolecular and synaptogenic effects of the rapid-acting antidepressant drug ketamine in the mouse brain","volume":"398","author":"Thelen","year":"2019","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1840","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3389\/fendo.2020.00417","article-title":"Anti-apoptotic actions of allopregnanolone and ganaxolone mediated through membrane progesterone receptors (PAQRs) in neuronal cells","volume":"11","author":"Thomas","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1845","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1017\/S0033583510000168","article-title":"The structural basis of function in Cys-loop receptors","volume":"43","author":"Thompson","year":"2010","journal-title":"Quarterly Reviews of Biophysics"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1865","series-title":"The age of anxiety: A history of America\u2019s turbulent affair with tranquilizers","author":"Tone","year":"2009"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1870","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2020.146889","article-title":"Mice lacking spinal \u03b12GABAA receptors: Altered GABAergic neurotransmission, diminished GABAergic antihyperalgesia, and potential compensatory mechanisms preventing a hyperalgesic phenotype","volume":"1741","author":"Tudeau","year":"2020","journal-title":"Brain Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.108035_bb1875","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s13311-020-00951-1","article-title":"\u03b16GABAA receptor positive modulators alleviate migraine-like grimaces in mice via compensating GABAergic deficits in Trigeminal Ganglia","volume":"18","author":"Tzeng","year":"2020","journal-title":"Neurotherapeutics."},{"key":"10.1016\/j.pharmthera.2021.108035_bb1880","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12090879","article-title":"Uncovering new drug properties in target-based drug-drug similarity networks","volume":"12","author":"Udrescu","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1885","author":"Ulrich"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1890","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/acn3.408","article-title":"First-in-man allopregnanolone use in super-refractory status epilepticus","volume":"4","author":"Vaitkevicius","year":"2017","journal-title":"Annals of Clinical Translational Neurology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1895","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/ejp.1365","article-title":"Trigeminal neuropathic pain development and maintenance in rats are suppressed by a positive modulator of \u03b16 GABAA receptors","volume":"23","author":"Vasovi\u0107","year":"2019","journal-title":"European Journal of Pain"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1900","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25040999","article-title":"Allosteric GABAA receptor modulators\u2014A review on the most recent heterocyclic chemotypes and their synthetic accessibility","volume":"25","author":"Vega Alanis","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1905","doi-asserted-by":"crossref","first-page":"104010","DOI":"10.1016\/j.bioorg.2020.104010","article-title":"Design, synthesis and neuropharmacological evaluation of new 2,4-disubstituted-1,5-benzodiazepines as CNS active agents","volume":"101","author":"Verma","year":"2020","journal-title":"Bioorganic Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.108035_bb6002","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1046\/j.1365-2125.2002.t01-10-01714.x","article-title":"Biomarkers for the effects of benzodiazepines in healthy volunteers","volume":"55","author":"de Visser","year":"2003","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1920","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.coph.2004.08.006","article-title":"GABAA receptor subtypes: Any clues to the mechanism of benzodiazepine dependence?","volume":"5","author":"Wafford","year":"2005","journal-title":"Current Opinion in Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1925","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.coph.2005.10.004","article-title":"Gaboxadol--a new awakening in sleep","volume":"6","author":"Wafford","year":"2006","journal-title":"Current Opinion in Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1940","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s13311-017-0555-6","article-title":"Open-label allopregnanolone treatment of men with fragile X-associated tremor\/ataxia syndrome","volume":"14","author":"Wang","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1945","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.wneu.2018.11.076","article-title":"The effectiveness of antiepileptic medications as prophylaxis of early seizure in patients with traumatic brain injury compared with placebo or no treatment: A systematic review and meta-analysis","volume":"122","author":"Wat","year":"2019","journal-title":"World Neurosurgery"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1950","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40263-016-0403-y","article-title":"Diazepam in the treatment of moderate to severe alcohol withdrawal","volume":"31","author":"Weintraub","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1965","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2125.1990.tb03616.x","article-title":"Respiratory and sedative effects of clobazam and clonazepam in volunteers","volume":"29","author":"Wildin","year":"1990","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1975","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/275551a0","article-title":"Labelling of benzodiazepine receptors in vivo","volume":"275","author":"Williamson","year":"1978","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1980","series-title":"Accidental medical discoveries: How tenacity and pure dumb luck changed the world","author":"Winters","year":"2016"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1985","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2020.172854","article-title":"mGlu2\/3 receptor antagonism: A mechanism to induce rapid antidepressant effects without ketamine-associated side-effects","volume":"190","author":"Witkin","year":"2020","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1990","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.pbb.2017.04.009","article-title":"Further evaluation of the potential anxiolytic activity of imidazo[1,5-a][1,4]diazepin agents selective for \u03b12\/3-containing GABAA receptors","volume":"157","author":"Witkin","year":"2017","journal-title":"Pharmacology Biochemistry and Behavior"},{"key":"10.1016\/j.pharmthera.2021.108035_bb1995","series-title":"Burger\u2019s medicinal chemistry, drug discovery and development","article-title":"New and emerging antiepileptic drugs","author":"Witkin","year":"2021"},{"key":"10.1016\/j.pharmthera.2021.108035_bb2000","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1124\/jpet.119.260968","article-title":"The positive allosteric modulator of \u03b12\/3-containing GABAA receptors, KRM-II-81, is active in pharmaco-resistant models of epilepsy and reduces hyperexcitability after traumatic brain injury","volume":"372","author":"Witkin","year":"2020","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.108035_bb2005","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/bs.apha.2019.03.002","article-title":"Rapid-acting antidepressants","volume":"86","author":"Witkin","year":"2019","journal-title":"Advances in Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb2010","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.neuropharm.2018.05.006","article-title":"Bioisosteres of ethyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo [1,5-a][1,4]diazepine-3-carboxylate (HZ-166) as novel alpha 2,3 selective potentiators of GABAA receptors: Improved bioavailability enhances anticonvulsant efficacy","volume":"137","author":"Witkin","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb2015","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pbb.2019.02.013","article-title":"The \u03b12,3-selective potentiator of GABAA receptors, KRM-II-81, reduces nociceptive-associated behaviors induced by formalin and spinal nerve ligation in rats","volume":"180","author":"Witkin","year":"2019","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"key":"10.1016\/j.pharmthera.2021.108035_bb2020","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0031-6997(25)00468-5","article-title":"Benzodiazepines: Use, abuse, and consequences","volume":"44","author":"Woods","year":"1992","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.pharmthera.2021.108035_bb2025","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1007\/s12325-020-01354-6","article-title":"Limited utility for benzodiazepines in chronic pain management: A narrative review","volume":"37","author":"Wright","year":"2020","journal-title":"Advances in Therapy"},{"key":"10.1016\/j.pharmthera.2021.108035_bb2035","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/ejp.1009","article-title":"Inhibition of \u03b15 subunit-containing GABAA receptors facilitated spinal nociceptive transmission and plasticity","volume":"21","author":"Xue","year":"2017","journal-title":"European Journal of Pain"},{"key":"10.1016\/j.pharmthera.2021.108035_bb2040","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2017.00246","article-title":"Ganaxolone: A new treatment for neonatal seizures","volume":"11","author":"Yawno","year":"2017","journal-title":"Frontiers in Cellular Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.108035_bb2050","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1165\/rcmb.2015-0176OC","article-title":"Targeting the \u03b3-aminobutyric acid a receptor \u03b14 subunit in airway smooth muscle to alleviate bronchoconstriction","volume":"54","author":"Yocum","year":"2016","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb2055","doi-asserted-by":"crossref","first-page":"L385","DOI":"10.1152\/ajplung.00356.2018","article-title":"A novel GABAA receptor ligand MIDD0301 with limited blood-brain barrier penetration relaxes airway smooth muscle ex vivo and in vivo","volume":"316","author":"Yocum","year":"2019","journal-title":"American Journal of Physiology. Lung Cellular and Molecular Physiology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb2060","doi-asserted-by":"crossref","first-page":"7892","DOI":"10.1074\/jbc.RA118.007172","article-title":"A photoreactive analog of allopregnanolone enables identification of steroid-binding sites in a nicotinic acetylcholine receptor","volume":"294","author":"Yu","year":"2019","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.108035_bb2065","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.pharmthera.2021.108035_bb2070","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/bs.apha.2014.11.007","article-title":"Restoring the spinal pain gate: GABA(A) receptors as targets for novel analgesics","volume":"73","author":"Zeilhofer","year":"2015","journal-title":"Advances in Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.108035_bb2075","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s13311-019-00815-3","article-title":"HMGB1 is a therapeutic target and biomarker in diazepam-refractory status epilepticus with wide time window","volume":"17","author":"Zhao","year":"2020","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.pharmthera.2021.108035_bb2080","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.psychres.2019.07.006","article-title":"Brexanolone for postpartum depression: A meta-analysis of randomized controlled studies","volume":"279","author":"Zheng","year":"2019","journal-title":"Psychiatry Research"},{"key":"10.1016\/j.pharmthera.2021.108035_bb2085","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41586-018-0255-3","article-title":"Structure of a human synaptic GABAA receptor","volume":"559","author":"Zhu","year":"2018","journal-title":"Nature"},{"issue":"Suppl. 2","key":"10.1016\/j.pharmthera.2021.108035_bb2090","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/epi.13999","article-title":"Intramuscular allopregnanolone and ganaxolone in a mouse model of treatment-resistant status epilepticus","volume":"59","author":"Zolkowska","year":"2018","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.108035_bb2095","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s13311-020-00985-5","article-title":"Intranasal allopregnanolone confers rapid seizure protection: Evidence for direct nose-to-brain delivery","volume":"18","author":"Zolkowska","year":"2021","journal-title":"Neurotherapeutics."},{"key":"10.1016\/j.pharmthera.2021.108035_bb2100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ynstr.2019.100196","article-title":"Neurosteroids as novel antidepressants and anxiolytics: GABA-A receptors and beyond","volume":"11","author":"Zorumski","year":"2019","journal-title":"Neurobiology of Stress"},{"key":"10.1016\/j.pharmthera.2021.108035_bb2105","author":"Zuiker"},{"key":"10.1016\/j.pharmthera.2021.108035_bb2110","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/0269881115620435","article-title":"NS11821, a partial subtype-selective GABAA agonist, elicits selective effects on the central nervous system in randomized controlled trial with healthy subjects","volume":"30","author":"Zuiker","year":"2016","journal-title":"J Psychopharmacol (Oxford)"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725821002370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725821002370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:18:45Z","timestamp":1778627925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725821002370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":342,"alternative-id":["S0163725821002370"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2021.108035","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GABAkines \u2013 Advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA receptors","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2021.108035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108035"}}